Status: Not yet recruiting
Study to Evaluate the Safety of UF-KURE-BCMA CAR T-Cells in Advanced Myeloma
The goal of this study is to evaluate the safety of a new type of CAR T-cell, UF-KURE-BCMA, for the treatment of patients with advanced multiple myeloma that has not responded to other therapies. The main question is whether the use of these new CAR T-cells is safe for patients with this condition. Secondarily, the study will also look at the response of myeloma to this therapy.
Participants needed: 12
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Kure Cells, INCUpdated: May 28, 2026
Eligibility criteria
Age: ≥18 years at time of signing informed consent [+13]
Active CNS involvement by multiple myeloma [+9]